

FLASH Radiotherapy + Immunotherapy: A Promising Duo



“With Prouty Pilot funding, we have pioneered an experimental radiation therapy technique that could be the most significant radiation-based cancer treatment breakthrough in the past 75 years.”

P. JACK HOOPES, DVM, PhD



Community dogs like Ezra and Jack who have developed spontaneous, treatment-resistant, lethal cancer are receiving novel FLASH radiation therapy and immunotherapy in an NCI-supported clinical trial. The trial is designed with curative intent for the canine patients, but also to generate information that’s meaningful to the FDA for the start of FLASH RT-immunotherapy human clinical trials.

STUDY NAME FLASH radiotherapy treatment of spontaneous canine tumors

PRINCIPAL INVESTIGATORS Rongxiao Zhang, PhD // David Gladstone, ScD // Kayla Duval, PhD // Cao Xu, PhD // Eugene Demidenko, PhD // Petr Bruza, PhD // Bassem Zaki, MD // Brian Pogue, PhD // P. Jack Hoopes, DVM, PhD

FOCUS To improve ultra-high dose rate FLASH radiation therapy when delivered alone and with immunotherapy to treat cancer.

Using a novel radiation therapy technique that spares normal tissues, but not tumor tissue, will allow for higher tumor dose and more tumors cured.

We are conducting this study on the world’s first modified medical linear accelerator, created by Dartmouth scientists, that is reversibly convertible between conventional and FLASH radiotherapy modes.

